webinar recording available - register to watch
The Australian Advantage: De-risk your early phase trials
As COVID-19 continues to spread across the United States, clinical trial sites and R&D labs are short-staffed and many are closed. Australia, though, has controlled the coronavirus outbreak – bioanalytical labs, CROs and sites are open for business and, as recognized as an essential service by the Australian Government, have been working throughout the pandemic. In this webinar, we’ll discuss the many advantages of moving your early phase trials to Australia, from models of speed, efficiency, and cost advantages, to the advanced medical facilities available for development. We will hear how Australia offers rapid solutions for new or delayed trials, as well as savings of up to 50% on clinical trial costs.
SPONSORED BY
SHARE ON
